Johns Hopkins Drug Discovery
80
page-template,page-template-full_width,page-template-full_width-php,page,page-id-80,page-child,parent-pageid-23,bridge-core-3.0.5,qi-blocks-1.0.5,qodef-gutenberg--no-touch,qodef-qi--no-touch,qi-addons-for-elementor-1.5.5,qode-page-transition-enabled,ajax_fade,page_not_loaded,,qode-theme-ver-29.1,qode-theme-bridge,disabled_footer_bottom,wpb-js-composer js-comp-ver-6.9.0,vc_responsive,elementor-default,elementor-kit-3247,x-shortcodes-v3_0_5

Neurofibromatosis Therapeutic Acceleration Program

The Neurofibromatosis Therapeutic Acceleration Program (NTAP) is a privately funded non-profit organization dedicated solely to developing effective treatments for patients with neurofibromatosis type 1-associated plexiform neurofibromas. NTAP uses a highly collaborative approach that brings together patients, clinicians, researchers, industry, and government to determine where resources are most effectively deployed to produce meaningful treatments. Dr. Barbara Slusher, the director of the JHDD program, is actively involved in a number of collaborative projects ranging from basic to clinical and translational research.